1. Top
  2. About Triple I

About Triple I

In recent years, the financial burden of global health has been increasing, especially on low and middle income countries (LMICs). Against this background, the mobilization of private capital through sustainable financing as well as public finance is fundamental in achieving the SDGs by 2030.

Impact investment refers to investments that intend to generate a measurable socially and/or environmentally beneficial impact alongside a financial return. In 2013, the United Kingdom announced the establishment of the Social Impact Investment Taskforce under its G8 Presidency. The UK initiative promoted impact investing as a means of tackling the most difficult social development problems. Since then, the global impact investing market size is expanding rapidly and is estimated to be US$ 1.164 trillion in 2021, of which about 7% is invested in healthcare and 6% in WASH.

At the G7 Hiroshima Summit in 2023, the leaders emphasized the important role of the private sector toward sustainable financing in global health, including through impact investments. The leaders endorsed the "Impact Investment Initiative for Global Health" (Triple I for GH), an initiative to raise awareness and share best practices on impact investment in global health. Triple I for GH was launched at the timing of the United Nations General Assembly High Level Meetings in September 2023.

12022 Sizing the Impact Investing Market by GIIN

Partners of Triple I for GH can demonstrate globally their endeavors to improve access to health for people in LMICs, to solve Global Health issues, and contribute to a more sustainable world while increasing their corporate value

G7 HIROSHIMA SUMMIT 2023
For More Details
Concept note of Triple I for GH published at G7 Hiroshima Summitpdf
G7 Hiroshima Leaders' Communiqué

Objectives and
Activities

  1. Raise awareness of impact investment in Global Health by showcasing best practices
  2. Increase transparency of impact investment in Global Health by promoting discussions and building up expertise on measurement, verification and disclosure
  3. Increase investment opportunities in Global Health by facilitating networking and knowledge exchange as well as identifying the thematic opportunities

Principles

  • To promote projects/ financial transactions which intend to address global health issues especially in LMICs such as achieving Universal health coverage (UHC) and/or strengthening prevention, preparedness, and response (PPR) for future pandemics, or create positive impacts in global health, especially in the target areas outlined below.
  • To promote projects/ financial transactions focused on products/services which mainly target increasing access to and affordability of health services and products in LMICs, and are better suited to reduce inequalities globally.
  • To promote projects/financial transactions with measurable social impacts/outcomes that could be reported, reviewed and verified with sound evidence.
  • To promote other efforts such as capacity building related to the mobilization of finance whose outcomes/impacts could be reported, reviewed with sound evidence.
  • To conduct research, exchange views on, and share good practices or challenges in impact investments in global health among partners for further development of impact investing/impact transparency.
  • To promote impact investments and impact transparency in global health.

Target Areas

  1. Health areas would include: communicable diseases including HIV/AIDS, tuberculosis, malaria, polio, measles, cholera, neglected tropical diseases (NTDs), antimicrobial resistance (AMR), non-communicable diseases (NCDs) including mental health conditions, sexual and reproductive health and rights (SRHR), maternal, newborn, child and adolescent health, healthy ageing, nutrition, water, sanitation and hygiene (WASH), and gender lens investment in health
  2. Products and technologies would include: drugs, diagnostics, vaccines, devices, personal protective equipment, software/AI (digital health solutions),
  3. Services and access would include: pandemic preparedness, delivery chains/logistics, local manufacturing, financial protection incl. health insurances and mitigation of catastrophic medical expenses, end-user service provider ecosystem (this includes areas such as primary health care, health system strengthening): essential public health functions including disease surveillance and response
For More Details
Operational Guidelinespdf
Annex1: Reporting Guidelines and Frameworkpdf
Annex2: Participation Formpdf Participation Form Examplepdf

Governance

Co-Chairs
  • Mr.Ken Shibusawa
    Mr.Ken Shibusawa
    CEO, Shibusawa & Company, Inc.
    CEO and Founder, &Capital Inc.
    Chairman, Commons Asset Management
    Member of the Council on "The New Form of Capitalism"
    GSG Japan NAB Chair
    Mr.Ken Shibusawa
    Mr.Ken Shibusawa
    CEO, Shibusawa & Company, Inc.
    CEO and Founder, &Capital Inc.
    Chairman, Commons Asset Management
    Member of the Council on "The New Form of Capitalism"
    GSG Japan NAB Chair

    Ken Shibusawa founded in 2001, Shibusawa and Company, Inc., and in 2008, Commons Asset Management. In 2021, he joined Brunswick Group as senior advisor.
    He has extensive market experience at JP Morgan, Goldman Sachs, and Moore Capital, a global macro hedge fund, where he was the representative managing director of the Tokyo Office. He is also co-chair of Global South-Africa Committee at Keizai Doyukai (Japan Association of Corporate Executives), advisor to the Office of the President at the University of Tokyo, member of various government panels, including Prime Minister Kishida's Council on New Capitalism, and a steering group member of UNDP SDG Impact.
    In 2022, he was named as board member of the newly founded International Foundation for Valuing Impact, as special advisor to the ISSB (International Sustainability Standards Boards) chair. In 2023, he founded &Capital, Inc., an impact fund management company for Africa.

  • Mr. Steve Davis
    Mr. Steve Davis
    Senior Advisor with McKinsey & Company,
    Stanford Graduate School of Business Lecturer and Global Health Faculty Fellow,
    Member of the Council on Foreign Relations
    Mr. Steve Davis
    Mr. Steve Davis
    Senior Advisor with McKinsey & Company,
    Stanford Graduate School of Business Lecturer and Global Health Faculty Fellow,
    Member of the Council on Foreign Relations

    Steve Davis serves as a Senior Advisor for McKinsey & Company, as a Lecturer at the Stan­ford Graduate School of Business, and as a member of the Council on Foreign Relations. Steve has deep experience, and sits on numerous boards and advisory groups, focused on the intersection of business, innovation, and social impact. He most recently served as Executive Strategic Advisor and Interim Director, China Country Office, for the Bill & Melin­da Gates Foundation, as co-chair of the World Health Organization's Digital Health Technical Advisory Group, and as a Distinguished Fellow for the World Economic Forum. Steve is the former President & CEO of PATH, a leading global health innovation organization; former Director of Social Innovation at McKinsey; former CEO of Corbis, a digital media pioneer; and as an attorney with K&L Gates. With degrees from Princeton University, University of Washington, and Columbia Law School, Steve also is the author of Undercurrents: Channeling Outrage to Spark Practical Activism (Wiley 2020), and speaks and writes frequently on topics related to corporate engagement in social impact, social innovation, and digital health . He lives with his family in Seattle, Washington.

  • Dr. Ayoade Alakija
    Dr. Ayoade Alakija
    The board chair of FIND,
    the World Health Organization (WHO) Special Envoy for the Access to COVID-19 Tools (ACT) Accelerator, and co-chairs the Principals Group.
    Dr. Ayoade Alakija
    Dr. Ayoade Alakija
    The board chair of FIND,
    the World Health Organization (WHO) Special Envoy for the Access to COVID-19 Tools (ACT) Accelerator, and co-chairs the Principals Group.

    Dr. Ayoade Alakija is a renowned global health leader with expertise in pandemic preparedness and health security and diplomacy. With over two decades in the field, her dedication to equitable access became especially pronounced during COVID-19. As FIND's board chair and the WHO Special Envoy for the ACT-Accelerator, she focuses on creating transformative impacts, particularly for the Global South.

    In her role as Nigeria's Chief Humanitarian Coordinator, she adeptly managed responses to humanitarian crises, and steered the Oslo Humanitarian Conference for Nigeria and the Lake Chad region. As the Chair of the African Vaccine Delivery Alliance, she has been pivotal in championing Africa's voice for access to medical countermeasures.

    Dr. Alakija is a staunch advocate for women's equity, believing in investing in women not just as a gender initiative but as a profitable business decision. Her voice consistently champions justice, echoing both in influential boardrooms and at the grassroots level.

Steering Committee
The Steering Committee will support the co-chairs in the implementation of the Triple I.
※The Steering Committee will be promptly set up after launch of Triple I.

Partners

As of March 19, 2024

Advisory & Advocacy Partners

As of March 19, 2024

Implementation / knowledge Partners

  • Bill & Melinda Gates Foundation
  • GSG Driving real impact
  • Global Impact Investing Network  -GIIN
  • ift Impact Taskforce

Secretariat

  • Cabinet Secretariat of Japan

Thank you for visiting us.
In order to provide better usage of this website and improve our services, we ask that you consent to the acquisition and use of cookies based on our policy.

About cookies